Business
Balchem makes specialty ingredients for nutrition, health and industrial uses.
Balchem grew revenue, remained profitable, generated positive free cash flow at a 20.2% operating margin. High margins and free cash flow remained strong while capital spending outgrew revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 8.8%OK
- Profitability — Net income grew 20.5% to $154.845M from $128.475MOK
- Cash flow — Free cash flow grew 18.3% to $173.067M from $146.338MOK
- Margins — Operating margin expanded 100 bps to 20.18%OK
- Accounting — High margins and free cash flow remained strong while capital spending outgrew revenueNote
- Insiders — 0 purchases and 3 salesNote
Where the revenue comes from
Fiscal 2025, as BALCHEM CORP reports it. History and quarterly detail are in the app.
- Human Nutrition and Health$659.4M
- Animal Nutrition and Health$230.9M
- Specialty Products$141.0M
Leadership changes
From BALCHEM CORP's own filings, the day they're filed.
- Daniel Knutson · director · departureeff. 2024-09-20
- Joyce Lee · Director · departure
- Involuntary Termination · departure
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BALCHEM CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.